GTGareth M. Thomas

Gareth M. Thomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gareth M. Thomas has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Sabrina M. Holland

    Center for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, USA

    8 shared publications
  • Xiaotian Zhang

    Center for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, USA

    7 shared publications
  • Jingwen Niu

    Center for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, USA

    6 shared publications
  • Audrey Montersino

    Shriners Hospitals Pediatric Research Center (Center for Neurorehabilitation and Neural Repair), Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA

    5 shared publications
  • Hey-Kyeong Jeong

    Center for Neural Development and Repair, Lewis Katz School of Medicine at Temple University

    5 shared publications
  • Shaun S. Sanders

    Shriners Hospitals Pediatric Research Center (Center for Neurorehabilitation and Neural Repair), Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA

    5 shared publications

Latest Publications

  • Open Access

    GAPDH is tethered to axonal transport vesicles by S-acylation

    by Nisandi N. Herath, Jordan A. Kogut, Andrey A. Petropavlovskiy, Amelia H. Doerksen, Charlotte A. Townsend Bennie, Anthony Dang, Gareth M. Thomas, Dale D.O. Martin, Shaun S. Sanders

    Vesicle movement along axonal microtubules in neurons requires the ATP-dependent molecular motors dynein and kinesin. Fast axonal transport is fueled by ATP, provided by vesicle-associated glycolytic enzymes, but how these predicted soluble enzymes attach to vesicles in unclear. One potential mechanism is the protein lipid modification S-acylation, which involves the addition of long chain fatty acids to protein cysteine residues mediated by the ZDHHC (Asp–His–His–Cys) family of protein S-acyltransferases. Among the many effects this lipid modification imparts is an increase in protein localization to membranes. We found that eight of the ten glycolytic enzymes are S-acylated in the brain. Of the 10 glycolytic enzymes, we focused on glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as it is the first enzyme of the payoff phase of glycolysis. GAPDH is S-acylated on cysteine 247 by ZDHHC5 and ZDHHC17. Importantly, C247 point mutation impairs GAPDH association with vesicles in hippocampal neurons. Investigating the role of S-acylation in glycolytic enzyme localization will lead to novel insights into neuronal transport mechanisms and may also shed light on neurodegenerative disease pathology and potential drug targets.

  • Open Access

    Combinatorial chemistry identifies additional compounds that selectively inhibit DLK-dependent retrograde signaling while minimally affecting other axonal roles of DLK

    by Xiaotian Zhang, Heykyeong Jeong, Edward Melenski, John Gordon, Wayne E. Childers, Gareth M. Thomas

    Dual leucine-zipper kinase (DLK) is implicated in at least two distinct processes that drive neurodegeneration: retrograde (axon-to-soma) signaling to activate pro-degenerative transcription programs, and axon-intrinsic action to drive Wallerian and Wallerian-like axon degeneration. Inhibiting DLK-dependent signaling is thus an attractive neuroprotective strategy, but compounds that inhibit all cellular pools of DLK cause unintended side effects. We recently successfully deployed a complementary approach to identify compounds that selectively block DLK retrograde (axon-to-soma) signaling and subsequent neurodegeneration by inhibiting acute, axonal palmitoylation of DLK. Here, we explored chemical space for one of our two most effective compounds and identified multiple analogs that are equally neuroprotective in a model of transcription-dependent neurodegeneration that requires DLK-dependent retrograde signaling. In contrast, our original hits and these additional analogs had minimal effect in two models of DLK-dependent, but transcription-independent, distal axon degeneration. Moreover, our original hits did not phenocopy the stabilization of axon survival factor proteins that is a well-described effect of conventional DLK kinase domain inhibitors. These findings reveal additional potential neuroprotective compounds and further support the notion that the pool of DLK that conveys axonal retrograde signals can be selectively targeted therapeutically.


  • Open Access

    DACIT device for axon cancer cell interaction testing in 2D and 3D

    by Ines Velazquez-Quesada, Vahid Alizadeh, Kara Allison, Elizaveta Belova, Svetllana Kallogjerovic, Natasha Hesketh, Xiaotian Zhang, Gareth Thomas, Erkan Tüzel, Bojana Gligorijevic


  • Open Access

    Micro-scale control of oligodendrocyte morphology and myelination by the intellectual disability-linked protein acyltransferase ZDHHC9

    by Hey-Kyeong Jeong, Estibaliz Gonzalez-Fernandez, Ilan Crawley, Julia M Coakley, Jinha Hwang, Dale Do Martin, Shernaz X Bamji, Jong-Il Kim, Shin H Kang, Gareth M Thomas

    Mutations in the X-linked ZDHHC9 gene cause cognitive deficits in humans, with a subset of patients suffering from epilepsy. X-linked intellectual disability (XLID) is often ascribed to neuronal deficits, but here we report that expression of human and mouse ZDHHC9 orthologs is far higher in myelinating oligodendrocytes (OLs) than in other CNS cell types. ZDHHC9 codes for a protein acyltransferase (PAT), and we found that ZDHHC9 is the most highly expressed PAT in OLs. Wild-type ZDHHC9 localizes to Golgi outposts in OL processes, but other PATs and XLID mutant forms of ZDHHC9 are restricted to OL cell bodies. Using genetic tools for OL progenitor fate tracing and sparse cell labeling, we show that mice lacking Zdhhc9 have grossly normal OL development but display extensive morphological and structural myelin abnormalities. Consistent with the hypothesis that these deficits are OL-autonomous, they are broadly phenocopied by acute Zdhhc9 knockdown in cultured conditions. Finally, we found that ZDHHC9 palmitoylates Myelin Basic Protein (MBP) in heterologous cells, and that palmitoylation of MBP is impaired in the Zdhhc9 knockout brain. Our findings provide critical insights into the mechanisms of ZDHHC9 -associated XLID and shed new light on the palmitoylation-dependent control of myelination.


  • Open Access

    Novel neuroprotective strategy based on inhibition of acute axonal palmitoylation of dual leucine-zipper kinase

    by Azita Minaei, Xiaotian Zhang, Gareth M. Thomas

  • Open Access

    Micro-Scale Control of Oligodendrocyte Morphology and Myelination by the Intellectual Disability-Linked Protein Acyltransferase ZDHHC9

    by Hey-Kyeong Jeong, Estibaliz Gonzalez-Fernandez, Ilan Crawley, Julia M Coakley, Jinha Hwang, Dale Do Martin, Shernaz X Bamji, Jong-Il Kim, Shin H Kang, Gareth M Thomas

    Mutations in the X-linked ZDHHC9 gene cause cognitive deficits in humans, with a subset of patients suffering from epilepsy. X-linked intellectual disability (XLID) is often ascribed to neuronal deficits, but here we report that expression of human and mouse ZDHHC9 orthologs is far higher in myelinating oligodendrocytes (OLs) than in other CNS cell types. ZDHHC9 codes for a protein acyltransferase (PAT), and we found that ZDHHC9 is the most highly expressed PAT in OLs. Wild type ZDHHC9 localizes to Golgi outposts in OL processes, but other PATs and XLID mutant forms of ZDHHC9 are restricted to OL cell bodies. Using genetic tools for OL progenitor fate tracing and sparse cell labeling, we show that mice lacking Zdhhc9 have grossly normal OL development but display extensive morphological and structural myelin abnormalities. Consistent with the hypothesis that these deficits are OL-autonomous, they are broadly phenocopied by acute Zdhhc9 knockdown in cultured conditions. Finally, we found that ZDHHC9 palmitoylates Myelin Basic Protein (MBP) in heterologous cells, and that palmitoylation of MBP is impaired in the Zdhhc9 knockout brain. Our findings provide critical insights into the mechanisms of ZDHHC9-associated XLID and shed new light on the palmitoylation-dependent control of myelination.

  • Open Access

    Inhibiting acute, axonal DLK palmitoylation is neuroprotective and avoids deleterious effects of cell-wide DLK inhibition

    by Xiaotian Zhang, Heykyeong Jeong, Jingwen Niu, Sabrina M. Holland, Brittany N. Rotanz, John Gordon, Margret B. Einarson, Wayne E. Childers, Gareth M. Thomas

    Inhibiting dual leucine-zipper kinase (DLK) could potentially ameliorate diverse neuropathological conditions, but a direct inhibitor of DLK’s kinase domain caused unintended side effects in human patients, indicative of neuronal cytoskeletal disruption. We sought a more precise intervention and show here that axon-to-soma pro-degenerative signaling requires acute, axonal palmitoylation of DLK. To identify potential modulators of this modification, we screened >28,000 compounds using a high-content imaging readout of DLK’s palmitoylation-dependent subcellular localization. Several hits alter DLK localization in non-neuronal cells, reduce DLK retrograde signaling and protect cultured dorsal root ganglion neurons from neurodegeneration. Mechanistically, the two most neuroprotective compounds selectively prevent DLK’s stimulus-dependent palmitoylation and subsequent recruitment to axonal vesicles, but do not affect palmitoylation of other axonal proteins assessed and avoid the cytoskeletal disruption associated with direct DLK inhibition. Our hit compounds also reduce pro-degenerative retrograde signaling in vivo, revealing a previously unrecognized neuroprotective strategy.


  • Open Access

    Novel inhibitors of acute, axonal DLK palmitoylation are neuroprotective and avoid the deleterious side effects of cell-wide DLK inhibition

    by Xiaotian Zhang, Heykyeong Jeong, Jingwen Niu, Sabrina M. Holland, Brittany N. Rotanz, John Gordon, Margret B. Einarson, Wayne E. Childers, Gareth M. Thomas

    Dual leucine-zipper kinase (DLK) drives acute and chronic forms of neurodegeneration, suggesting that inhibiting DLK signaling could ameliorate diverse neuropathological conditions. However, direct inhibition of DLK’s kinase domain in human patients and conditional knockout of DLK in mice both cause unintended side effects, including elevated plasma neurofilament levels, indicative of neuronal cytoskeletal disruption. Indeed, we found that a DLK kinase domain inhibitor acutely disrupted the axonal cytoskeleton and caused vesicle aggregation in cultured dorsal root ganglion (DRG) neurons, further cautioning against this therapeutic strategy. In seeking a more precise intervention, we found that retrograde (axon-to-soma) pro-degenerative signaling requires acute, axonal palmitoylation of DLK and hypothesized that modulating this post-translational modification might be more specifically neuroprotective than cell-wide DLK inhibition. To address this possibility, we screened >28,000 compounds using a high-content imaging assay that quantitatively evaluates DLK’s palmitoylation-dependent subcellular localization. Of the 33 hits that significantly altered DLK localization in non-neuronal cells, several reduced DLK retrograde signaling and protected cultured DRG neurons from DLK-dependent neurodegeneration. Mechanistically, the two most neuroprotective compounds selectively prevent stimulus-dependent palmitoylation of axonal pools of DLK, a process crucial for DLK’s recruitment to axonal vesicles. In contrast, these compounds minimally impact DLK localization and signaling in healthy neurons and avoid the cytoskeletal disruption associated with direct DLK inhibition. Importantly, our hit compounds also reduce pro-degenerative retrograde signaling in vivo, suggesting that modulating DLK’s palmitoylation-dependent localization could be a novel neuroprotective strategy.


  • Open Access

    Device for Axon - Cancer cell Interaction Testing in 2D & 3D: DACIT

    by Ines Velazquez-Quesada, Vahid Alizadeh, Kara Allison, Elizaveta Belova, Svetllana Kallogjerovic, Natasha Hesketh, Xiaotian Zhang, Gareth Thomas, Erkan Tuzel, Bojana Gligorijevic

    Summary: There is increasing interest in studying the role of peripheral innervation in tumor growth and metastasis. However, in vitro studies of interactions between cancer cells and axonal projections are technically challenging. To address this, we have developed a microfluidic Device for Axon-Cancer cell Interaction Testing in 2D and 3D (DACIT). We show that DACIT successfully separates neuronal soma from the axons and cancer cells into two compartments, which can be exposed to similar, or different growth conditions, depending on the experimental needs. We compare neoaxonogenesis using either the PC-12 cell line or primary embryonic or adult sensory neurons, demonstrating superior neurite growth in primary cells. Additionally, we show that DACIT can accommodate assessing growth and 3D invasion of tumor spheroids, due to its unique height profile. Hence, DACIT can be used to analyze cancer cell interactions with axons in most typical cell biology assays such as proliferation, invasion, and calcium activity which we demonstrate on examples of imaging transients in GCaMP6-labeled neurons, invadopodia assay, and 3D cancer spheroid invasion.